C4 Therapeutics is a biotechnology business based in the US. C4 Therapeutics shares (CCCC) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.62 – an increase of 2.53% over the previous week. C4 Therapeutics employs 110 staff and has a trailing 12-month revenue of around $35.6 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $1.62 |
|---|---|
| 52-week range | $1.09 - $7.66 |
| 50-day moving average | $1.87 |
| 200-day moving average | $4.29 |
| Wall St. target price | $16.07 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.52 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.74 from 2025-05-02
| 1 week (2025-04-29) | 10.13% |
|---|---|
| 1 month (2025-04-04) | 32.82% |
| 3 months (2025-02-06) | -51.40% |
| 6 months (2024-11-06) | -70.85% |
| 1 year (2024-05-06) | -74.07% |
|---|---|
| 2 years (2023-05-05) | -47.11% |
| 3 years (2022-05-05) | 8.8 |
| 5 years (2020-05-02) | N/A |
| Revenue TTM | $35.6 million |
|---|---|
| Gross profit TTM | $-75,053,000 |
| Return on assets TTM | -20.17% |
| Return on equity TTM | -45.58% |
| Profit margin | -295.96% |
| Book value | $3.06 |
| Market Capitalization | $123.6 million |
TTM: trailing 12 months
We're not expecting C4 Therapeutics to pay a dividend over the next 12 months.
You may also wish to consider:
Over the last 12 months, C4 Therapeutics's shares have ranged in value from as little as $1.085 up to $7.66. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while C4 Therapeutics's is 3.124. This would suggest that C4 Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
To put C4 Therapeutics's beta into context you can compare it against those of similar companies.
C4 Therapeutics, Inc. , a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 clinical trials targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting BRAF V600 mutant that is in Phase 1/2 clinical trials to treat melanoma, colorectal cancer, and other solid malignancies; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor with an L858R mutation in non-small cell lung cancer. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. ; Biogen MA, Inc.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Some of the best stock trading apps for beginners include SoFi, Robinhood, Public, Stash, Opto and more. Compare your options here.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
Fidelity is best for its extensive tools and resources, while Robinhood is a popular choice for its simple, easy-to-use platform.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
SoFi Invest is a no-fee commissions platform with both active and automated investment accounts.